HK1021318A1 - Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation - Google Patents

Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation

Info

Publication number
HK1021318A1
HK1021318A1 HK00100173.9A HK00100173A HK1021318A1 HK 1021318 A1 HK1021318 A1 HK 1021318A1 HK 00100173 A HK00100173 A HK 00100173A HK 1021318 A1 HK1021318 A1 HK 1021318A1
Authority
HK
Hong Kong
Prior art keywords
proliferation
cd2a antibody
inhibiting
cell activation
cd2a
Prior art date
Application number
HK00100173.9A
Other languages
English (en)
Inventor
Herve Bazin
Dominique Latinne
Ruth Kaplan
Thomas Kieber-Emmons
Christina E Postema
Mary E White-Scharf
Original Assignee
Biotransplant Inc
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotransplant Inc, Univ Catholique Louvain filed Critical Biotransplant Inc
Publication of HK1021318A1 publication Critical patent/HK1021318A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK00100173.9A 1996-08-16 2000-01-11 Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation HK1021318A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/013281 WO1998007444A1 (en) 1996-08-16 1996-08-16 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION

Publications (1)

Publication Number Publication Date
HK1021318A1 true HK1021318A1 (en) 2000-06-09

Family

ID=22255617

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00100173.9A HK1021318A1 (en) 1996-08-16 2000-01-11 Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation

Country Status (11)

Country Link
EP (1) EP0959899B9 (xx)
JP (1) JP2001521374A (xx)
AT (1) ATE432080T1 (xx)
AU (1) AU737602B2 (xx)
CA (1) CA2262546C (xx)
DE (1) DE69637943D1 (xx)
DK (1) DK0959899T3 (xx)
ES (1) ES2327980T3 (xx)
HK (1) HK1021318A1 (xx)
PT (1) PT959899E (xx)
WO (1) WO1998007444A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
DE60330468D1 (de) 2002-08-21 2010-01-21 Revivicor Inc Schweine ohne jegliche expression funktioneller alpha-1,3-galactosyltransferase
US8106251B2 (en) 2002-08-21 2012-01-31 Revivicor, Inc. Tissue products derived from porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
CA2548080A1 (en) 2003-11-05 2005-05-26 University Of Pittsburgh Porcine isogloboside 3 synthase protein, cdna, genomic organization, and regulatory region
US20230365687A1 (en) * 2020-06-23 2023-11-16 Zelarion Malta Limited Anti-cd2 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2700893A (en) 1952-08-06 1955-02-01 Teddy A Kudlacik Balancing device
US4798806A (en) * 1980-01-08 1989-01-17 Ortho Pharmaceutical Corporation Compositions and methods using a monoclonal antibody to a human T cell antigen
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
PT687300E (pt) * 1993-03-05 2002-03-28 Univ Catholique Louvain Anticorpo lo-cd2a e sua utilizacao para a inibicao da activacao e proliferacao de celulas-t
CN113299700A (zh) 2021-05-08 2021-08-24 武汉华星光电半导体显示技术有限公司 一种显示面板及其制备方法

Also Published As

Publication number Publication date
ES2327980T3 (es) 2009-11-05
ATE432080T1 (de) 2009-06-15
JP2001521374A (ja) 2001-11-06
WO1998007444A1 (en) 1998-02-26
DE69637943D1 (de) 2009-07-09
DK0959899T3 (da) 2009-09-07
EP0959899A4 (en) 2005-01-12
EP0959899B1 (en) 2009-05-27
PT959899E (pt) 2009-08-28
CA2262546A1 (en) 1998-02-26
AU737602B2 (en) 2001-08-23
CA2262546C (en) 2009-03-17
EP0959899B9 (en) 2009-10-21
EP0959899A1 (en) 1999-12-01
AU6953296A (en) 1998-03-06

Similar Documents

Publication Publication Date Title
EP1003552A4 (en) ANTIBODIES DIRECTED AGAINST LO-CD2a AND USE THEREOF TO INHIBIT THE ACTIVATION AND PROLIFERATION OF T-LYMPHOCYTES
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
EP0313378A3 (en) Methods and compositions for transient elimination of humoral immune antibodies
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
HU9202214D0 (en) Medical preparative containing antigen-antibody complexes and its utilization
HK1021318A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
IL111105A0 (en) Methods of inhibiting phagocytosis
WO2000078814A3 (en) LO-CD2b ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION
WO1998021314A3 (en) Method of promoting B-cell proliferation and activation and of modulating the immune system
Qiao et al. Regulation of T cell reactivities by intestinal mucosa
GB2259706B (en) Porcine adipocyte antigens and their use in the immunological control of fat
EP0321094A3 (en) Treatment of factor viii inhibitors
Minai et al. Mechanism of IL-10 Production by a CD8+ T Cell Clone
AU3481389A (en) Antibodies to human papillomavirus latent proteins, diagnostic systems and methods
CA2311679A1 (en) Use of a soluble recombinant human cd40l protein for inhibiting in vivo immune response

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: UNIVERSITE CATHOLIQUE DE LOUVAIN, 1, PLACE DE LA UNIVERSITE 1348 LOUVAIN-LA-NEUVE, BELGIUM

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130816